Digoxin
- Generic Name
- Digoxin
- Brand Names
- Digox, Lanoxin
- Drug Type
- Small Molecule
- Chemical Formula
- C41H64O14
- CAS Number
- 20830-75-5
- Unique Ingredient Identifier
- 73K4184T59
- Background
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...
- Indication
Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...
- Associated Conditions
- Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
- Associated Therapies
- -
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 113
- Registration Number
- NCT05444556
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT05395117
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05389722
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT05064488
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
ALT-801 DDI Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04972396
- Locations
- 🇦🇺
Q-Pharm, Herston, Queensland, Australia
🇦🇺CMAX Clinical Research, Adelaide, South Australia, Australia
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04887194
- Locations
- 🇺🇸
Goshen Health, Goshen, Indiana, United States
🇺🇸MultiCare Health System, Tacoma, Washington, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
A Drug Interaction Study of ACH-0145228
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04709081
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04621669
- Locations
- 🇨🇳
Affiliated Hospital of Qingdao University, Qingdao, China
Drug-drug Interaction Study of Gepotidacin
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT04493931
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT04268394
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.